Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Affected assets and topics
Why it matters
Foghorn Therapeutics has closed a $50 million registered direct financing at a 30% premium, selling 2.03 million shares of common stock at $6.71 per share. This financing is expected to provide the company with additional capital to support its research and development efforts. The premium at which the financing was closed indicates strong investor interest in the company.
Article tone
Expected market reaction
Market impact analysis based on bullish sentiment with 90% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 32206
Original source
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered direct financing at a 30% premium. The registered direct offering included the sale of 2,030,314 shares of common stock at $6.71 per share (issue price). Certain investors received pre-funded warrants to
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on January 14, 2026. Analysis and insights provided by AnalystMarkets AI.